9.4 Research and development costs

Accounting for R&D Costs

Research and development costs represent what companies spend to create new products, services, or processes. The core accounting challenge is this: R&D spending might lead to hugely profitable innovations, or it might lead nowhere. That uncertainty drives most of the accounting rules you need to know for this topic.

R&D Costs vs. Capital Expenditures

These two get mixed up often, but the distinction matters.

Capital expenditures are costs to acquire or improve long-term assets like property, plant, and equipment. The future benefit is reasonably certain (you bought a building, and it's there), so you capitalize and depreciate them.

R&D costs are expenditures tied to developing something new. The future benefit is not certain. You might spend millions on a drug that never gets approved. Because of that uncertainty, R&D costs are generally expensed as incurred rather than capitalized.

Criteria for R&D Activities

Not every expense qualifies as R&D. To count as R&D, an activity must involve:

• Planned search or investigation — a systematic effort aimed at discovering new knowledge or developing new products/processes. Routine testing or quality control doesn't qualify.
• Discovery of new knowledge — the goal is to learn something that didn't exist before, not just apply what's already known.
• Uncertainty of future benefits — there's no guarantee the work will produce a commercially viable result. This uncertainty is exactly why the default accounting treatment is to expense these costs.

Accounting Treatment of R&D Costs

Expensing R&D Costs

Under US GAAP, R&D costs are expensed as incurred. Full stop. You recognize them as expenses on the income statement in the period the spending happens.

Under IFRS, research costs are also expensed as incurred, but development costs can be capitalized if specific criteria are met (covered below in the IFRS vs. US GAAP section).

Rationale for Expensing

The logic is conservative: since you can't reliably predict whether R&D will generate future revenue, recognizing it as an asset would risk overstating the balance sheet. Expensing immediately keeps reported assets grounded in what's reasonably certain.

Impact on Financial Statements

• R&D expenses reduce net income and EPS in the period they're incurred.
• The balance sheet is not inflated by uncertain future benefits.
• Companies with heavy R&D spending (think pharmaceuticals or tech) can appear less profitable in the short term, even if that spending fuels long-term growth. Keep this in mind when comparing companies across industries.

R&D Costs on the Balance Sheet

Even though R&D costs hit the income statement rather than the balance sheet, companies still have disclosure obligations:

• They must report the total amount of R&D costs incurred during the period.
• They must provide a description of R&D activities being undertaken.

The notes to the financial statements often give additional detail: specific projects underway, expected timelines, and anticipated outcomes. These notes are where analysts look to understand a company's innovation pipeline.

R&D Arrangements

Funding from Third Parties

Companies sometimes receive outside funding for R&D from government agencies, partners, or other companies. This funding can come as grants, contracts, or collaborative agreements.

Accounting for Third-Party Funding

The accounting treatment depends on the terms of the arrangement:

1. Funding contingent on success with repayment required — If the company must repay the funds when the R&D succeeds, it records a liability for the potential repayment obligation. The risk hasn't truly been transferred to the third party.
2. Non-refundable funding — If the company keeps the money regardless of outcome, it recognizes the funding as income in the period received.

The critical question is: who bears the risk of failure? If the company bears it, there's a liability. If the third party bears it, there's income.

R&D in Business Combinations

In-Process R&D (IPR&D)

When one company acquires another, it may pick up R&D projects that are still underway. These incomplete projects are called in-process R&D (IPR&D).

Valuation and Subsequent Treatment

Under US GAAP, IPR&D acquired in a business combination follows a specific path:

1. At acquisition: Recognize IPR&D as an indefinite-lived intangible asset at fair value.
2. Fair value measurement: Determined using valuation techniques such as the multi-period excess earnings method or the relief-from-royalty method.
3. After acquisition: The asset is not amortized but is subject to annual impairment testing.
4. Upon completion: Once the project is finished, reclassify the asset as a finite-lived intangible and begin amortizing it.
5. Upon abandonment: If the project is abandoned, write the asset down to zero (recognize an impairment loss).

This is a notable exception to the general rule of expensing R&D. Because the IPR&D was acquired at a measurable fair value in a transaction, it gets asset treatment.

Financial Ratios Impacted by R&D

Two ratios come up frequently when analyzing R&D spending:

R&D Intensity Ratio

$\text{R\&D Intensity Ratio} = \frac{\text{R\&D Expenses}}{\text{Total Revenues}}$

This measures how much of a company's revenue base is being directed toward R&D. A biotech firm might have a ratio above 20%, while a retailer's would be near zero.

R&D to Sales Ratio

$\text{R\&D to Sales Ratio} = \frac{\text{R\&D Expenses}}{\text{Total Sales}}$

Functionally very similar to the intensity ratio, this version specifically uses sales rather than total revenues. Both ratios help investors gauge how aggressively a company is investing in future innovation relative to its current size.

Tax Treatment of R&D Costs

R&D Tax Credits

Many jurisdictions offer tax credits to incentivize R&D investment. These credits reduce a company's tax liability based on qualifying R&D expenditures. The specific rules (what qualifies, credit percentages, caps) vary by country and sometimes by region within a country.

Timing Differences vs. Permanent Differences

The tax treatment of R&D can create differences between book income and taxable income:

• Timing differences arise when R&D expenses are recognized in different periods for financial reporting vs. tax purposes. For example, tax law might allow accelerated deduction of certain R&D costs that are expensed evenly for book purposes. These differences reverse over time and create deferred tax assets or liabilities.
• Permanent differences occur when an R&D expense is recognized for book purposes but is never deductible for tax purposes (or vice versa). These don't reverse and directly affect the effective tax rate.

Comparison of IFRS vs. US GAAP

This is one of the most testable differences in this unit.

IFRS Capitalization Criteria for Development Costs

Under IFRS (IAS 38), development costs must be capitalized once all six of the following criteria are met. If even one is not satisfied, the costs are expensed:

1. Technical feasibility of completing the intangible asset
2. Intention to complete and use or sell it
3. Ability to use or sell the intangible asset
4. Probable future economic benefits — the company can demonstrate how the asset will generate them (e.g., a market exists for it)
5. Adequate resources — technical, financial, and other resources are available to finish development and use or sell the asset
6. Reliable measurement — the company can reliably measure the expenditure attributable to the asset during development

Once capitalized, development costs are amortized over the asset's useful life and tested for impairment.